Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2344–2346.

https://doi.org/10.1182/blood-2022-166826

Published: 2022

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Anna Sureda, Ana Pilar González, Javier Núñez, Javier Briones, Fátima De la Cruz, Domingo Domenech Eva, Francisca Maria Hernandez, María José Terol, Elena Amutio, Raul Cordoba, Carmen Martínez, Miriam Moreno, Antonia Rodriguez Izquierdo, Raquel Del Campo, Richard Greil, Samuel Romero, Ramón Garcia-Sanz

Blood (2021) 138 (Supplement 1): 2459.

https://doi.org/10.1182/blood-2021-150200

Published: 2021

Journal Articles

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Pilar Martínez, MD, Tomás Palanques Pastor, Jose Luiz Lopez Lorenzo, MD, Javier Cornago Navascués, MD, Gabriela Rodriguez-Macías, MD, Isabel Cano, MD, Montserrat Arnan Sangerman, María-Belén Vidriales, MDPhD, Jesús Lorenzo Algarra, Maria Angeles Foncillas, Pilar Herrera Puente, Carmen Botella, Susana Vives, MD, Angela Figuera Alvarez, MD PhD, Laida Cuevas Palomares, Marta Sobas, MDPhD, Alejandro Contento-Gonzalo, MD, Rebeca Cuello, MD, María Elena Amutio Diez, MD, Maria Dunia De Miguel, MD, Begoña Navas, MD, Juan Miguel Bergua Burgues, MD, Teresa Bernal del Castillo, MD PhD, María Carmen Mateos Rodríguez, MD, Erik de Cabo López, MD, Ana Carolina Franco Villegas, MD, Raimundo García-Boyero, MD, Cristian Escolano Escobar, MD, Cristina Seri, MD, Carlos Cervero, MD, Alicia Roldán Pérez, Maria Lourdes Hermosin, MD, Marta Cervera, MD, María Teresa Olave, MD, Paola Sandra Villafuerte Gutierrez, MD, Almudena De Laiglesia, MD, Josefina Serrano, MD, María Josefa Najera Irazu, MD, Jose Luis Piñana Sanchez, Miguel Ángel Sanz, MD, Joaquin Martinez-Lopez, MD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138471

Published: 2020

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2786.

https://doi.org/10.1182/blood.V126.23.2786.2786

Published: 2015

Journal Articles

Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens

Blood (2013) 122 (21): 3922.

https://doi.org/10.1182/blood.V122.21.3922.3922

Published: 2013

Journal Articles

Efficacy and Effectiveness of Azacitidine In Elderly Patients with Acute Myeloid Leukemia and Blasts Counts below 30%: Experience of the Spanish Registry

Regina García, Monserrat Arnar, Elisa Luño, Joan Bargay, Ma Mar Romero, Juan Besalduch, Elena Amutio, Raquel Garrido, Fernando Carnicero, Grupo Andaluz de Smd

Blood (2010) 116 (21): 4354.

https://doi.org/10.1182/blood.V116.21.4354.4354

Published: 2010

Journal Articles

Clinical Experience with Azacitidine In Secondary Myelodysplastic Syndrome In Spain

Regina García, Guillermo F Sanz, MD, PhD, Dunia de Miguel Llorente, Benet Nomdedeu, MD, M Mar Romero, Teresa Bernal, Juan Besalduch, Elena Amutio, Salut Brunet, Grupo Andaluz de Smd

Blood (2010) 116 (21): 1852.

https://doi.org/10.1182/blood.V116.21.1852.1852

Published: 2010

Journal Articles

Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.

Pau Montesinos, Jordi Esteve, Edo Vellenga, Concha Rivas, Salut Brunet, Montserrat Arnan, Jose D. Gonzalez, Pedro Sanchez, Joaquín Díaz-Mediavilla, Amparo Verdeguer, Lourdes Escoda, Elena Amutio, Vicente Rubio, Inmaculada Perez, Ramon Guardia, Javier Bueno, Bob Lowenberg, Miguel A. Sanz

Blood (2009) 114 (22): 1062.

https://doi.org/10.1182/blood.V114.22.1062.1062

Published: 2009

Journal Articles

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.

Blood (2009) 114 (22): 845.

https://doi.org/10.1182/blood.V114.22.845.845

Published: 2009

Journal Articles

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Blood (2009) 113 (4): 775–783.

https://doi.org/10.1182/blood-2008-07-168617

Published: 2009

Journal Articles

Risk-adapted treatment of acute promyelocytic leukemia with all- trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

Blood (2008) 112 (8): 3130–3134.

https://doi.org/10.1182/blood-2008-05-159632

Published: 2008

Journal Articles

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

Blood (2008) 111 (7): 3395–3402.

https://doi.org/10.1182/blood-2007-07-100669

Published: 2008

Journal Articles

Secondary Acute Myeloid Leukemia and Myelodysplastic Syndromes Following ATRA and Anthracycline Monochemotherapy Treatment for Acute Promyelocytic Leukemia.

Pau Montesinos, MD, Jose D. Gonzalez, PHD, Chelo Rayon, PHD, Javier de la Serna, PHD, Juan Bergua, PHD, Jordi Esteve, PHD, Mar Tormo, PHD, Edo Vellenga, PHD, Elena Amutio, PHD, Guillermo Deben, PHD, Miguel Sanz, PHD

Blood (2007) 110 (11): 1838.

https://doi.org/10.1182/blood.V110.11.1838.1838

Published: 2007

Journal Articles

FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.

Pau Montesinos, MD, Marcos Gonzalez, PhD, Maria Calasanz, PhD, Pascual Bolufer, PhD, Dolors Colomer, PhD, Jose Roman, PhD, Maria Teresa Gomez, PhD, Joaquin Martinez, PhD, Elena Amutio, PhD, Miguel Sanz, PhD

Blood (2006) 108 (11): 2348.

https://doi.org/10.1182/blood.V108.11.2348.2348

Published: 2006

Journal Articles

All- trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

Miguel A. Sanz, Edo Vellenga, Chelo Rayón, Joaquín Díaz-Mediavilla, Concha Rivas, Elena Amutio, Jesús Arias, Guillermo Debén, Andrés Novo, Juan Bergua, Javier de la Serna, Javier Bueno, Silvia Negri, José M. Beltrán de Heredia, Guillermo Martín

Blood (2004) 104 (12): 3490–3493.

https://doi.org/10.1182/blood-2004-04-1642

Published: 2004

Journal Articles

Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.

Blood (2004) 104 (11): 2019.

https://doi.org/10.1182/blood.V104.11.2019.2019

Published: 2004

Journal Articles

Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA).

Blood (2004) 104 (11): 887.

https://doi.org/10.1182/blood.V104.11.887.887

Published: 2004

Journal Articles

Risk-adapted treatment of acute promyelocytic leukemia with all- trans -retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

Miguel A. Sanz, Guillermo Martín, Marcos González, Angel León, Chelo Rayón, Concha Rivas, Dolors Colomer, Elena Amutio, Francisco J. Capote, Gustavo A. Milone, Javier de la Serna, José Román, Eva Barragán, Juan Bergua, Lourdes Escoda, Ricardo Parody, Silvia Negri, María J. Calasanz, Pascual Bolufer

Blood (2004) 103 (4): 1237–1243.

https://doi.org/10.1182/blood-2003-07-2462

Published: 2004

NARROW

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens

Efficacy and Effectiveness of Azacitidine In Elderly Patients with Acute Myeloid Leukemia and Blasts Counts below 30%: Experience of the Spanish Registry

Clinical Experience with Azacitidine In Secondary Myelodysplastic Syndrome In Spain

Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Risk-adapted treatment of acute promyelocytic leukemia with all- trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

Secondary Acute Myeloid Leukemia and Myelodysplastic Syndromes Following ATRA and Anthracycline Monochemotherapy Treatment for Acute Promyelocytic Leukemia.

FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.

All- trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.

Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA).

Risk-adapted treatment of acute promyelocytic leukemia with all- trans -retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only